| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/02/2004 | US20040171560 antineoplastic agents such as paclitaxel, teniposide, camptothecin and derivatives thereof; preferred solvent includes absolute or dehydrated alcohol |
| 09/02/2004 | US20040171559 stem cells require extracellular wnt signaling for proliferation and thus are rendered quiescent by administration of agents that block extracellular wnt signaling |
| 09/02/2004 | US20040171558 sulfamate; represented by topiramate; retinal embolism, ischemic optic neuropathy, macular degeneration, retinitis pigmentosa or Leber's disease |
| 09/02/2004 | US20040171557 treating or educating said cells ex vivo in the presence of: intermediary metabolite; antigens or epitopes associated with said disease, or the immune-mediated inflammatory response; re-administering to said subject said treated or educated cells |
| 09/02/2004 | US20040171556 Methods for inhibiting proteasome |
| 09/02/2004 | US20040171546 Regulation of lung tissue by hedgehog-like polypeptides and formulations and uses related thereto |
| 09/02/2004 | US20040171544 treating or preventing epithelial lesions in a mammal (e.g., a human) using trefoil domain-containing polypeptides |
| 09/02/2004 | US20040171541 combination comprising a polypeptide comprising the modulating sequence of the erythropoietin receptor and a non-peptide organic molecule in the treatment of anemia |
| 09/02/2004 | US20040171533 Methods and compositions for regulating adiopocytes |
| 09/02/2004 | US20040171532 coadministering a taxane and an oral bioavailability enhancing agent inhibitor of p-glycoprotein; preventing or reducing hypersensitivity or allergic reactions; anticancer agents |
| 09/02/2004 | US20040171528 Raise intracellular or extracellular or serum level of metabolite in subject |
| 09/02/2004 | US20040171527 Regulation of immune responses by manipulation of intermediary metabolite levels |
| 09/02/2004 | US20040171526 Raise intracellular or extracellular or serum level of metabolite in subject |
| 09/02/2004 | US20040171522 Raise the intracellular or extracellular or serum level of metabolite in subject |
| 09/02/2004 | US20040171520 Melanocortin receptor-specific peptidomimetics |
| 09/02/2004 | US20040171518 Compounds for protein stabilization and methods for their use |
| 09/02/2004 | US20040171155 Materials and methods for management of hyperacute rejection in human xenotransplantation |
| 09/02/2004 | US20040171150 Antisense nucleotide sequences for prevention and treatment of sepsis, viral infection, autoimmune and cell proliferative disorders |
| 09/02/2004 | US20040171127 Preparing oil/fat comprising triglycerides in which medium-chain fatty acids are bound to 1 and 3 positions and a polyunsaturated fatty acid is bound to the 2 position for use in foods, beverages and pharmaceutical agents; dietetics |
| 09/02/2004 | US20040171111 Polypeptide of a p53 protein-specific murin a/t-cell receptor, nucleic acids coding therefor and use thereof |
| 09/02/2004 | US20040171110 Novel member of the lysyl oxidase gene family |
| 09/02/2004 | US20040171108 Human excitatory amino acid transporter-2 gene promoter and uses thereof |
| 09/02/2004 | US20040171093 Methods for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses |
| 09/02/2004 | US20040171086 Selective modulation of TLR-mediated biological activity |
| 09/02/2004 | US20040171075 Modulation of protein functionalities |
| 09/02/2004 | US20040171073 Modulators which prevent lipid transport via blocking activity of scavenger receptors and for treating atheroscerotic disosrders; contraceptives |
| 09/02/2004 | US20040171033 Comprises modified nucleotide sequences for use in gene expression inhibition, viral defense, transposon silencing and treatment of metabolic disorders; antisense agents |
| 09/02/2004 | US20040170999 Nuclear hormone receptor ligand binding domain |
| 09/02/2004 | US20040170980 Molecules capable of binding to telomere and the like and method with the use of the same |
| 09/02/2004 | US20040170959 Methods for identifying antiviral oligonucleotides |
| 09/02/2004 | US20040170750 Edible composition and dosage form comprising an edible shell |
| 09/02/2004 | US20040170714 Bauhinia extracts |
| 09/02/2004 | US20040170713 To promote good health and as a dietary additive |
| 09/02/2004 | US20040170708 Topical application of mixtures comprising plant derived estrogens, 2-amino-5-(diaminomethylideneamino)pentanoic acid and 5-methyl-2-propan-2-yl-cyclohexan-1-ol, to induce urothelial sensory nerve regeneration |
| 09/02/2004 | US20040170706 Promotes good health by providing to a mammal essential saccharides which are the building blocks of glycoproteins |
| 09/02/2004 | US20040170704 Process for the manufacture of a herbal composition |
| 09/02/2004 | US20040170703 Reduction of reactive oxygen species in chronic wound management |
| 09/02/2004 | US20040170702 Method and composition for treating hypopigmentation of the hair and skin |
| 09/02/2004 | US20040170701 Pharmaceutical composition comprising copper, salicylic acid, vitamin c and zinc for use in treatment of different diseases such as bacterial or viral infection |
| 09/02/2004 | US20040170698 Water-soluble mixture of polyethylene glycol and sodium phosphate; useful for preparing the bowel prior to surgery or diagnostic procedures such as colonoscopies |
| 09/02/2004 | US20040170697 Amniotic apoptosis modulating substances |
| 09/02/2004 | US20040170695 Melt granulated composition and modified release dosage form prepared from said composition |
| 09/02/2004 | US20040170694 Therapeutic and prophylactic compositions including catalytic biomimetic solids and methods to prepare and use them |
| 09/02/2004 | US20040170691 Amoxycillin pellets |
| 09/02/2004 | US20040170690 Tablet comprising cetirizine and pseudoephedrine |
| 09/02/2004 | US20040170688 For once a week dosing |
| 09/02/2004 | US20040170685 Coated with biodegradable, bioactive polymers that promote endogenous healing at a site of stent implantation |
| 09/02/2004 | US20040170684 For therapy of incontinence |
| 09/02/2004 | US20040170683 Tablets comprising modafinil |
| 09/02/2004 | US20040170681 Fast acting paracetamol formulation containing a small amount of antacid |
| 09/02/2004 | US20040170680 For orally administering oxycodone to provide analgesic therapy beyond its relatively short half-life over an extended period of time, and having a duration of pain relief of at least 24-hours |
| 09/02/2004 | US20040170678 Liposomal antineoplastic drugs and uses thereof |
| 09/02/2004 | US20040170677 Method of drug loading in liposomes by gradient |
| 09/02/2004 | US20040170673 Adhesive emulsion for medical purposes made from ethylene-vinyl acetate copolymers and adhesive resins |
| 09/02/2004 | US20040170672 For therapy of patients suffering from schizophrenic psychoses |
| 09/02/2004 | US20040170668 Use of docosahexaenoic acid and arachidonic acid enhancing the growth of preterm infants |
| 09/02/2004 | US20040170667 Agents for relieving eye controlling function error |
| 09/02/2004 | US20040170659 containing urea and a carrier, with a pH of 4-6; treating disorders including those due to changes in normal keratinization, epidermal formation or pilosebaceous function, such as acne, psoriasis, seborrhea, ingrown hairs and pseudofolliculitis barbae, and hyperpigmented skin |
| 09/02/2004 | US20040170655 preserving normal sebum homeostasis; prophylaxis and treatment of greasy hair and dandruff; prophylaxis and treatment of mild forms of acne, and for the prophylaxis and control of seborrhea and blemished skin. |
| 09/02/2004 | US20040170654 bolus injection to skin; increased systemic absorption produced compared to absorption produced on delivering the agonist subcutaneously by bolus injection; particularly applicable to tricyclic nitrogen-containing compounds, e.g., R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinoline-2(1H)-thione |
| 09/02/2004 | US20040170653 recognised by CD8-positive cytotoxic T-lymphocytes as a peptide antigen and causes a CTL-induced lysis and/or apoptosis of tumor or leukemia cell; has the amino acid sequence LLGDLFGV, which corresponds to the amino acid positions 81 to 88 of the hdm2 proto-oncoprotein |
| 09/02/2004 | US20040170650 Pharmaceutical compositions having a modified vehicle |
| 09/02/2004 | US20040170645 especially brown algae, red algae or green algae containing a polysaccharide that is Rhamnose, Xylose, Galactose, and/or Mannose; may be mixed with food stuffs |
| 09/02/2004 | US20040170632 Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan |
| 09/02/2004 | US20040170617 treating with an antibacterial agent and/or a probiotic mixture; used for Attention Deficit Disorder, Depression, biopolar disorder, Alzheimer's disease, Parkinson's Disease, Whipple's Disease, Tourette's Syndrome, Asperger's syndrome, Pervasive Development Disorder, gastrointestinal disorders, etc. |
| 09/02/2004 | US20040170603 Using radiolabeled annexin; radiotherapy for tumors |
| 09/02/2004 | US20040170599 Gastrointestinal disorders; anticancer agents; sustained release |
| 09/02/2004 | US20040170597 Modified polyurethane; biocompatibility; biodegradation |
| 09/02/2004 | US20040170595 Multi-arm block copolymers as drug delivery vehicles |
| 09/02/2004 | US20040170591 Dermatological composition comprising nicotinic acid or an amide, and a sphingoid base |
| 09/02/2004 | US20040170585 Skin disorders |
| 09/02/2004 | US20040170581 Mixture containing a caffeic acid ester |
| 09/02/2004 | US20040170576 Preparation for saliva flow |
| 09/02/2004 | US20040170573 Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route |
| 09/02/2004 | US20040170572 Delivery of rizatriptan or zolmitriptan through an inhalation route |
| 09/02/2004 | US20040170571 Delivery of diazepam through an inhalation route |
| 09/02/2004 | US20040170570 Delivery of rizatriptan or zolmitriptan through an inhalation route |
| 09/02/2004 | US20040170569 Dosage forms that rapidly produces peak plasma concentrations; heating a thin layer of the drug on a solid support to form a vapor; and passing air through the heated vapor to produce aerosol particles having less than 10% drug degradation products |
| 09/02/2004 | DE19910682B4 Verwendung eines Kombinationspräparates zur Therapie einer Fibrat-induzierten Hyperhomocysteinämie The use of a combination product for the treatment of a fibrate-induced hyperhomocysteinemia |
| 09/02/2004 | DE10307857A1 Verfahren zur Gewinnung und zum Einsatz von Wertstoffen aus Nebenprodukten der Gemüseverarbeitung Process for the recovery and use of recyclable materials from by-products of vegetable processing |
| 09/02/2004 | DE10307389A1 Anti-Aknemittel Anti-acne |
| 09/02/2004 | DE10307387A1 New (omega-1)-hydroxy fatty acid esters useful for preparing cosmetic, pharmaceutical or dermatological compositions, especially anti-acne compositions |
| 09/02/2004 | DE10306987A1 Zubereitung auf Basis von Teebaumöl sowie Verfahren zu ihrer Herstellung und ihre Verwendung Preparation on the basis of tea tree oil and processes for their preparation and their use |
| 09/02/2004 | DE10306177A1 Seaweed oil, essential oil, terpene, phosphatidylserine, omega-3 fatty acid, lanolin, selin or D-panthenol concentrate containing excess polysorbate useful as an additive for foods, cosmetics, pharmaceuticals |
| 09/02/2004 | DE10306083A1 Erkennungsmoleküle gerichtet gegen ein Survivin-Gen und die Verwendung dieser Recognition molecules directed against a survivin gene and the use of these |
| 09/02/2004 | DE10305984A1 Salze organischer Säuren mit Clopidogrel und deren Verwendung zur Herstellung phamazeutischer Formulierungen Salts of organic acids with clopidogrel and to the use thereof for the preparation of formulations phamazeutischer |
| 09/02/2004 | DE10258007A1 Neue aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung New aromatic Fluorglycosidderivate, pharmaceutical compositions containing them and their use |
| 09/02/2004 | CA2833559A1 Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions |
| 09/02/2004 | CA2767153A1 Phenylenediamine urotensin-ii receptor antagonists and ccr-9 antagonists |
| 09/02/2004 | CA2517005A1 A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid |
| 09/02/2004 | CA2517004A1 Methods of stabilizing azithromycin during storage by packaging in a gas impermeable container |
| 09/02/2004 | CA2516790A1 Formulations of glucocorticoids to treat pathologic ocular angiogenesis |
| 09/02/2004 | CA2516782A1 Use of steroids to treat ocular disorders |
| 09/02/2004 | CA2516748A1 Anthelmintic agents and insecticidal compositions |
| 09/02/2004 | CA2516736A1 Drug delivery from embolic agents |
| 09/02/2004 | CA2516679A1 The use of antimuscarinic drugs |
| 09/02/2004 | CA2516475A1 Oxazole-derivatives as ppar agonists |
| 09/02/2004 | CA2516471A1 Ferric organic compounds, uses thereof and methods of making same |
| 09/02/2004 | CA2516466A1 Regulation of blood pressure by coded nerve signals |
| 09/02/2004 | CA2516454A1 Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same |